| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 12 analysts have published ratings on Gilead Sciences (NASDAQ:GILD), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 9 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 6 | 0 | 0 |
Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $84.42, accompanied by a high estimate of $105.00 and a low estimate of $75.00. This current average represents a 5.15% decrease from the previous average price target of $89.00.
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Hartaj Singh | Oppenheimer | Maintains | Outperform | $105.00 | $105.00 |
| Colin Bristow | UBS | Lowers | Neutral | $75.00 | $81.00 |
| Mohit Bansal | Wells Fargo | Lowers | Equal-Weight | $78.00 | $84.00 |
| Salim Syed | Mizuho | Lowers | Buy | $90.00 | $101.00 |
| Robyn Karnauskas | Truist Securities | Lowers | Hold | $82.00 | $91.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $75.00 | $76.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $80.00 | $85.00 |
| Hartaj Singh | Oppenheimer | Lowers | Outperform | $105.00 | $115.00 |
| Olivia Brayer | Cantor Fitzgerald | Lowers | Neutral | $78.00 | $80.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $76.00 | $78.00 |
| Mohit Bansal | Wells Fargo | Lowers | Equal-Weight | $84.00 | $90.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $85.00 | $82.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Gilead Sciences's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -3.72% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Gilead Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 20.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.33%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.3%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.09.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GILD
